Morgan Stanley Hopes for Some Retail Therapy for Humana

In a report published Thursday, Morgan Stanley analyst Andrew Schenker reiterated an Equal-Weight rating on Humana (NYSE: HUM ). In the report, Morgan Stanley noted, “HUM maintained its 2014 EPS outlook of $7.25 to $7.75, but increased its Medicare Advantage, Part D, and commercial individual enrollment outlook on the heels